Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.9% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
1
users have commented on this narrative
39
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
0
users have commented on this narrative
14
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
15
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Northern Data
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Taiga Cloud And NVIDIA Partnership Will Drive Market Transformation
Key Takeaways Strategic expansion into AI and HPC, boosted by partnerships and technology, positions Northern Data to capture revenue growth in the generative AI market. Transitioning to carbon-neutral energy and advanced cooling tech may lower costs, while potential asset sales could fund AI-focused reinvestment.
View narrative
€36.60
FV
52.6% undervalued
intrinsic discount
41.96%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
9
users have followed this narrative
Updated
narrative
Gauzy
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Smart Glass Integration In Electric Vehicles Will Fuel Lasting Demand
Key Takeaways Broad industry diversification, strong OEM partnerships, and innovative smart glass tech position Gauzy for stable growth and reduced revenue volatility. Increased production capacity, operational efficiencies, and improved cash flow management support higher profitability and readiness for sustained market expansion.
View narrative
US$11.00
FV
n/a
intrinsic discount
49.66%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
Updated
narrative
UroGen Pharma
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
Office-Based Urology Therapies And Demographic Trends Will Redefine Care
Key Takeaways Successful ZUSDURI launch and pipeline expansion position UroGen for significant revenue growth and reduced product dependency. Alignment with industry care trends and robust commercialization strategy support premium pricing and improved long-term profitability.
View narrative
US$31.43
FV
n/a
intrinsic discount
70.04%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
12
users have followed this narrative
Updated
narrative
Neo Performance Materials
AN
AnalystConsensusTarget
Consensus Narrative from 2 Analysts
European Magnet Facility Expansion Will Support Clean Energy Demand
Key Takeaways Strategic expansion into European markets and focus on higher-margin products strengthen competitive positioning and operational margins. Diversified end-market exposure and localized supply chain strategies enhance revenue stability and reduce cyclical and geopolitical risks.
View narrative
CA$21.33
FV
n/a
intrinsic discount
-2.74%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
9
users have followed this narrative
Updated
narrative
Coronado Global Resources
AN
AnalystConsensusTarget
Consensus Narrative from 8 Analysts
Mammoth And Buchanan Expansion Will Drive Mixed Metallurgical Coal Trends
Key Takeaways Market confidence hinges on expansion projects, operational upgrades, and global steel demand driving sustainable growth, possibly overlooking execution risks and industry headwinds. Investor expectations rely on supply constraints and financial strength protecting earnings and returns, while underestimating potential decarbonization impacts and future cost pressures.
View narrative
AU$0.22
FV
40.6% overvalued
intrinsic discount
11.85%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
25
users have followed this narrative
Updated
narrative
Arcturus Therapeutics Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 9 Analysts
Late-Stage Trials And Vaccine Partnerships Will Strengthen Market Potential
Key Takeaways Advancement in late-stage clinical programs and partnerships positions the company to capture rare disease and vaccine market opportunities, enhancing revenue growth and competitiveness. Operational restructuring and prioritized pipeline extend financial runway, enabling focused investment in high-potential assets while lowering dilution risk and operating expenses.
View narrative
US$70.89
FV
n/a
intrinsic discount
33.29%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
37
users have followed this narrative
Updated
narrative
Lumentum Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 17 Analysts
Advanced Optical Demand Will Drive Cloud And AI Markets
Key Takeaways Surging demand in cloud, AI, and data centers drives growth, with constrained supply enabling higher margins and profitability. Manufacturing expansion, innovation, and strong customer adoption position the company for ongoing revenue and earnings gains.
View narrative
US$135.59
FV
n/a
intrinsic discount
21.93%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
13
users have followed this narrative
Updated
narrative
Cellebrite DI
AN
AnalystConsensusTarget
Consensus Narrative from 7 Analysts
Cloud SaaS Solutions Will Drive Digital Forensics Adoption
Key Takeaways Accelerating digital crime and security demands are boosting adoption of Cellebrite's forensic SaaS platforms, driving strong subscription growth and deeper customer relationships. Emphasis on privacy compliance, AI innovation, and recurring revenue is expanding market opportunities, supporting premium pricing, and improving margins and valuation prospects.
View narrative
US$23.00
FV
n/a
intrinsic discount
15.69%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
15
users have followed this narrative
Updated
narrative
AVITA Medical
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Medicare Resolution And Trauma Expansion Will Shape Future Wound Care
Key Takeaways Expanded reimbursement clarity and favorable clinical outcomes are boosting provider confidence, leading to broader hospital adoption and increased revenue opportunities. New product launches and operational efficiencies diversify market reach and support improved margins, positioning AVITA for long-term profitability.
View narrative
US$9.60
FV
n/a
intrinsic discount
42.60%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
20
users have followed this narrative
Updated
narrative
Value any company in seconds
Popular companies